Skip to main content

Angela Vidal Jordana

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Angela Vidal Jordana

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Incorporació Dr. Manuel Comabella a la RETICS en Esclerosis Múltiple

IP: Manuel Comabella Lopez
Collaborators: Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Herena Eixarch Ahufinger, Incorporació Dr. Manuel Comabella a la RETICS en Esclerosis Múltiple, Carmen Espejo Ruiz, Angela Vidal Jordana, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 225500
Reference: RD16/0015/0004
Duration: 01/01/2017 - 31/12/2022

Sol·licitud Juan Rodés

IP: Sol·licitud Juan Rodés
Collaborators: Angela Vidal Jordana, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 135000
Reference: JR16/00024
Duration: 01/01/2017 - 21/04/2020

Diagnostic and prognostic biomarkers in pediatric multiple sclerosis and related demyelinating disorders

IP: Diagnostic and prognostic biomarkers in pediatric multiple sclerosis and related demyelinating disorders
Collaborators: Cristina Auger Acosta, Alex Rovira Cañellas, Mireia Del Toro Riera, Angela Vidal Jordana, Luciana Midaglia Fernandez, Georgina Arrambide García
Funding agency: Fundació La Marató de TV3
Funding: 100000
Reference: 20141831
Duration: 22/05/2015 - 22/11/2018

Intensificació

IP: Intensificació
Collaborators: Angela Vidal Jordana, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: INT13/00302
Duration: 01/01/2014 - 31/12/2014

Related news

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

Related professionals

Borja Garcia Centrich

Borja Garcia Centrich

Gestió i Administració
Unitat legal
Legal Directorate
Read more
Pilar Bonet Palomares

Pilar Bonet Palomares

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
José Alonso Fajardo

José Alonso Fajardo

Shock, Organ Dysfunction and Resuscitation
Read more
Nuria Nogués Gálvez

Nuria Nogués Gálvez

Senior researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.